Treatment-free survival after discontinuation of immune checkpoint inhibitors in mNSCLC: a systematic review and meta-analysis

BACKGROUND: Recent research has suggested that patients with metastatic non-small cell lung cancer (mNSCLC) can achieve ongoing response after discontinuation of immune checkpoint inhibitor (ICI), but the best time to discontinue and the factors influencing efficacy remain unknown. METHOD: A systema...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Yue, Liu, Shan, Wang, Lixing, Liu, Yu, Zhang, Duohan, Zhao, Yinlong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373084/
https://www.ncbi.nlm.nih.gov/pubmed/37520573
http://dx.doi.org/10.3389/fimmu.2023.1202822

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373084/
https://www.ncbi.nlm.nih.gov/pubmed/37520573
http://dx.doi.org/10.3389/fimmu.2023.1202822

Ejemplares similares